| dc.contributor.author |
Tsivou, M |
en |
| dc.contributor.author |
Dimopoulou, HA |
en |
| dc.contributor.author |
Leontiou, I-P |
en |
| dc.contributor.author |
Georgakopoulos, DG |
en |
| dc.contributor.author |
Koupparis, M |
en |
| dc.contributor.author |
Atta-Politou, J |
en |
| dc.contributor.author |
Georgakopoulos, CG |
en |
| dc.date.accessioned |
2014-06-06T06:50:43Z |
|
| dc.date.available |
2014-06-06T06:50:43Z |
|
| dc.date.issued |
2010 |
en |
| dc.identifier.issn |
00098981 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/j.cca.2009.11.029 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/5132 |
|
| dc.subject |
Doping control analysis |
en |
| dc.subject |
Erythropoietin |
en |
| dc.subject |
Proteases |
en |
| dc.subject |
Stabilization |
en |
| dc.subject |
Urine |
en |
| dc.subject.other |
antibiotic agent |
en |
| dc.subject.other |
antifungal agent |
en |
| dc.subject.other |
erythropoietin |
en |
| dc.subject.other |
proteinase |
en |
| dc.subject.other |
proteinase inhibitor |
en |
| dc.subject.other |
recombinant erythropoietin |
en |
| dc.subject.other |
analytic method |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
chemoluminescence |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
doping |
en |
| dc.subject.other |
electrophoresis |
en |
| dc.subject.other |
enzymatic degradation |
en |
| dc.subject.other |
enzyme inactivation |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
immunoassay |
en |
| dc.subject.other |
incubation time |
en |
| dc.subject.other |
priority journal |
en |
| dc.subject.other |
protein degradation |
en |
| dc.subject.other |
qualitative analysis |
en |
| dc.subject.other |
quantitative analysis |
en |
| dc.subject.other |
urinalysis |
en |
| dc.subject.other |
Athletic Performance |
en |
| dc.subject.other |
Child, Preschool |
en |
| dc.subject.other |
Doping in Sports |
en |
| dc.subject.other |
Erythropoietin |
en |
| dc.subject.other |
Female |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Immunoassay |
en |
| dc.subject.other |
Recombinant Proteins |
en |
| dc.subject.other |
Sensitivity and Specificity |
en |
| dc.title |
Stabilization of human urine doping control samples: III. Recombinant human erythropoietin |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/j.cca.2009.11.029 |
en |
| heal.publicationDate |
2010 |
en |
| heal.abstract |
Background: The tampering of athlete's urine samples by the addition of proteolytic enzymes during the doping control sampling procedure was reported recently. The aim of the current study, funded by the World Anti-Doping Agency (WADA), was the application of a stabilization mixture in urine samples to chemically inactivate proteolytic enzymes and improve the electrophoteric signal of erythropoietin (EPO) in human urine. Methods: The stabilization mixture applied was a combination of antibiotics, antimycotic substances and protease inhibitors. A series of incubation experiments were conducted under controlled conditions in the presence and absence of the stabilization mixture in urine aliquots spiked with six proteases. Two different analytical techniques were applied for the qualitative and quantitative EPO measurement: isoelectric focusing (IEF) and chemiluminescent immunoassay respectively. Results: The addition of the chemical stabilization mixture into urine aliquots substantially improved EPO detection in the presence of proteolytic enzymes following incubation at 37 °C or storage at - 20 °C. Conclusions: The results of this study indicated that the stabilization of urine prior to the sample collection procedure with the proposed chemical mixture might prove to be a useful tool for the preservation of anti-doping samples. © 2009 Elsevier B.V. All rights reserved. |
en |
| heal.journalName |
Clinica Chimica Acta |
en |
| dc.identifier.issue |
5-6 |
en |
| dc.identifier.volume |
411 |
en |
| dc.identifier.doi |
10.1016/j.cca.2009.11.029 |
en |
| dc.identifier.spage |
448 |
en |
| dc.identifier.epage |
452 |
en |